Human Anti-NGF Recombinant Antibody (clone mab 911)

Rats received weekly subcutaneous injection of 10 mg/kg muMab 911 or PBS on days 0, 7, 14, and 21 post intra-articular injection of MIA or saline. Preventative muMab 911 robustly prevented MIA-induced changes in weight-bearing asymmetry (A, B) and attenuated hindpaw withdrawal thresholds (C, D). Statistical comparison of groups at each timepoint: two-Way ANOVA with Bonferroni's post-hoc tests, *P < 0.05, **P < 0.01, ***P < 0.001: MIA vs saline; #P < 0.05, ##P < 0.01, ###P < 0.001 muMab 911 vs PBS. Note saline muMab 911 group did not differ from the saline PBS group, and is not shown for clarity (n = 10 rats per group). Preventative treatment with muMab 911 did not significantly alter MIA-induced cartilage damage (n = 9–10 per group) (E) or synovial inflammation (n = 8–9 per group) (F). *P < 0.05, **P < 0.01, ***P < 0.001 vs saline-PBS. Comparisons between Areas Under Curve were performed using a Mann–Whitney U-test. Comparisons of histology between groups used a Kruskal Wallis test with Dunn's post hoc. A, C: data are mean ± SEM; B, D, E, F: data are median and interquartile range. M911: muMab 911.

Xu, L., Nwosu, L. N., Burston, J. J., Millns, P. J., Sagar, D. R., Mapp, P. I.,... & Chapman, V. (2016). The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis and cartilage, 24(9), 1587-1595.

Histological sections of osteochondral (A–C) or synovial (D–F) tissue. A; PBS-treated saline-injected control showing an intact joint with smooth cartilage, normal joint margin and chondrocyte morphology. B; 1 mg MIA-injected PBS-treated rat showing OA structural pathology: cartilage damage (green arrows); chondrocyte loss (green arrows); subchondral bone changes (asterisk). C: M911-treated MIA-injected rat exhibited similar pathology to the MIA-PBS treated rat (B). D: 1–2 cell deep synovial lining layer (blue arrow) in PBS-treated saline-injected control. E; Synovial hyperplasia (red arrows) in 1 mg MIA-injected PBS-treated rat. F: Synovium from a M911-treated MIA-injected rat exhibited similar pathology to the MIA-PBS treated rat (E). Photomicrographs show haematoxylin and eosin stained sections of knee tissue from a rat with the median pathology score from each group. Scale bars = 200 μm. F = femur, m = meniscus, c = cartilage, t = tibia, sb = subchondral bone and s = synovium.

Xu, L., Nwosu, L. N., Burston, J. J., Millns, P. J., Sagar, D. R., Mapp, P. I.,... & Chapman, V. (2016). The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis and cartilage, 24(9), 1587-1595.

(A) The number of TRAP positive osteoclasts in the tibial plateau was significantly increased in MIA rats receiving vehicle treatment. Preventative treatment with muMab 911 significantly reduced the number of TRAP positive osteoclasts in MIA rats. Data are mean ± SEM, n = 9–10 per group. (B) Therapeutic muMab 911 significantly attenuated the MIA-induced increase in the number of TRAP positive osteoclasts in the tibial plateau. Data are mean ± SEM n = 8–10 per group. Statistical comparison was carried out using one-Way ANOVA with Bonferroni's post-hoc tests, *P < 0.05, **P < 0.01. Representative images of osteoclasts at the osteochondral junction of the tibial plateau in a saline-PBS rat (left), MIA-PBS rat (middle) and MIA-muMab 911 rat (right) in the preventative study (C) and therapeutic study (D). Images were taken with a Zeiss Axioplan microscope at 10× magnification. Arrows indicate multinucleated TRAP positive osteoclasts. M911: muMab 911.

Xu, L., Nwosu, L. N., Burston, J. J., Millns, P. J., Sagar, D. R., Mapp, P. I.,... & Chapman, V. (2016). The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis and cartilage, 24(9), 1587-1595.

Rats received subcutaneous injection of 10 mg/kg muMab 911 or PBS on days 14 and 21 post intra-articular injection of MIA. muMab 911 treatment alleviated MIA-induced changes in weight-bearing asymmetry (A, B) and attenuated hindpaw withdrawal thresholds (C, D). Statistical comparison of muMab 911 and PBS treatment on pain behaviour, A, C are mean ± SEM (n = 8–10 rats per group): two-Way ANOVA with Bonferroni's post-hoc tests, #P < 0.05, ###P < 0.001. Note behavioural data from rats which received intra-articular injection of saline were comparable to the preventative study, and are not shown for clarity. B, D are median and interquartile range, comparison of these data was performed with a Mann–Whitney U-test, #P < 0.05, ##P < 0.01. Therapeutic treatment with muMab 911 did not significantly alter MIA-induced cartilage damage (E) or synovial inflammation (F) (n = 8–10 rats per group). E, F are median and interquartile range, comparisons between groups used a Kruskal Wallis test with Dunn's post hoc comparison. *P < 0.05, **P < 0.01, ***P < 0.001. M911: muMab 911.

Xu, L., Nwosu, L. N., Burston, J. J., Millns, P. J., Sagar, D. R., Mapp, P. I.,... & Chapman, V. (2016). The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis and cartilage, 24(9), 1587-1595.